MX2015008058A - Lactamas fusionadas de arilo y heteroarilo. - Google Patents
Lactamas fusionadas de arilo y heteroarilo.Info
- Publication number
- MX2015008058A MX2015008058A MX2015008058A MX2015008058A MX2015008058A MX 2015008058 A MX2015008058 A MX 2015008058A MX 2015008058 A MX2015008058 A MX 2015008058A MX 2015008058 A MX2015008058 A MX 2015008058A MX 2015008058 A MX2015008058 A MX 2015008058A
- Authority
- MX
- Mexico
- Prior art keywords
- aryl
- heteroaryl fused
- compounds
- fused lactams
- salts
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000003951 lactams Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invención se refiere a compuestos de la fórmula general (I) (ver Fórmula) en la cual R1, R2, U, V, L, M, R5, m, X, Y y Z son como aquí se definieron, y las sales farmacéuticamente aceptables del mismo, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos para utilizar esos compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, que incluye cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740596P | 2012-12-21 | 2012-12-21 | |
| PCT/IB2013/060682 WO2014097041A1 (en) | 2012-12-21 | 2013-12-05 | Aryl and heteroaryl fused lactams |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015008058A true MX2015008058A (es) | 2015-10-30 |
Family
ID=49917684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008058A MX2015008058A (es) | 2012-12-21 | 2013-12-05 | Lactamas fusionadas de arilo y heteroarilo. |
| MX2020002924A MX2020002924A (es) | 2012-12-21 | 2015-06-19 | Lactamas fusionadas de arilo y heteroarilo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002924A MX2020002924A (es) | 2012-12-21 | 2015-06-19 | Lactamas fusionadas de arilo y heteroarilo. |
Country Status (46)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| PE20151433A1 (es) | 2012-12-21 | 2015-10-16 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| AP2016009605A0 (en) * | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| WO2015193768A1 (en) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| KR20170068603A (ko) * | 2014-10-28 | 2017-06-19 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| WO2016101956A2 (en) | 2014-12-23 | 2016-06-30 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| HUE049090T2 (hu) * | 2015-03-27 | 2020-09-28 | Syngenta Participations Ag | Heterobiciklusos származékok mint mikrobiocidek |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| KR20180081587A (ko) | 2015-11-19 | 2018-07-16 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 벤조푸란 유도체, 이의 제조 방법 및 의학에서의 이의 용도 |
| CA3023157A1 (en) * | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| US20200262813A1 (en) * | 2016-11-11 | 2020-08-20 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| TWI772424B (zh) | 2017-05-18 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種苯并呋喃類衍生物游離鹼的晶型及製備方法 |
| MY201580A (en) | 2017-05-18 | 2024-03-02 | Jiangsu Hengrui Medicine Co | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor |
| CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
| US11529344B2 (en) | 2017-11-14 | 2022-12-20 | Pfizer Inc. | EZH2 inhibitor combination therapies |
| PT3746446T (pt) | 2018-01-31 | 2022-07-18 | Mirati Therapeutics Inc | Inibidores de prc2 |
| CA3102777A1 (en) * | 2018-06-07 | 2019-12-12 | The Regents Of The University Of Michigan | Prc1 inhibitors and methods of treatment therewith |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| WO2020086857A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
| CN111320582A (zh) * | 2018-12-17 | 2020-06-23 | 江苏恩华药业股份有限公司 | 一种类酰胺类衍生物及其中间体的制备方法 |
| KR102689665B1 (ko) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
| JP7387907B2 (ja) | 2020-08-13 | 2023-11-28 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規なジオキソロイソキノリノン誘導体化合物及びその用途｛ｎｏｖｅｌ ｄｉｏｘｏｌｏｉｓｏｑｕｉｎｏｌｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝ |
| CN116457348B (zh) * | 2021-02-26 | 2024-11-26 | 南京迈晟科技有限责任公司 | Ezh2抑制剂及其用途 |
| CN120476107A (zh) | 2022-12-15 | 2025-08-12 | 先正达农作物保护股份公司 | 可用作杀有害生物剂的新型的二环-甲酰胺化合物 |
| CN118978498B (zh) * | 2024-10-22 | 2025-04-01 | 浙江雅辰药物科技股份有限公司 | 一种5-羟甲基四氢呋喃-3-醇的制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| RU2765155C2 (ru) | 2010-09-10 | 2022-01-26 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
| WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3323820B1 (en) * | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2760452A4 (en) | 2011-09-30 | 2015-04-01 | Glaxosmithkline Llc | METHODS OF TREATING CANCER |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2884848C (en) | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| MX344879B (es) | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| DK2935312T3 (en) | 2012-12-21 | 2018-10-22 | Hoffmann La Roche | Peptides as oxytocin agonists |
| PE20151433A1 (es) | 2012-12-21 | 2015-10-16 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos |
| AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
-
2013
- 2013-05-12 UA UAA201505087A patent/UA111305C2/uk unknown
- 2013-12-05 AP AP2015008574A patent/AP2015008574A0/xx unknown
- 2013-12-05 RS RS20200917A patent/RS60582B9/sr unknown
- 2013-12-05 LT LTEP17206218.4T patent/LT3339303T/lt unknown
- 2013-12-05 SI SI201330958T patent/SI2935238T1/en unknown
- 2013-12-05 ME MEP-2020-147A patent/ME03793B/me unknown
- 2013-12-05 JP JP2015548808A patent/JP5909308B2/ja active Active
- 2013-12-05 MY MYPI2020003405A patent/MY192259A/en unknown
- 2013-12-05 HR HRP20180060TT patent/HRP20180060T1/hr unknown
- 2013-12-05 EA EA201590879A patent/EA028317B1/ru unknown
- 2013-12-05 GE GEAP201313863A patent/GEP201706718B/en unknown
- 2013-12-05 PT PT172062184T patent/PT3339303T/pt unknown
- 2013-12-05 KR KR1020157019806A patent/KR101712441B1/ko not_active Expired - Fee Related
- 2013-12-05 RS RS20180103A patent/RS56815B1/sr unknown
- 2013-12-05 NZ NZ708801A patent/NZ708801A/en not_active IP Right Cessation
- 2013-12-05 BR BR112015014678-3A patent/BR112015014678B1/pt not_active IP Right Cessation
- 2013-12-05 PL PL13817739T patent/PL2935238T3/pl unknown
- 2013-12-05 PL PL17206218T patent/PL3339303T3/pl unknown
- 2013-12-05 DK DK13817739.9T patent/DK2935238T3/en active
- 2013-12-05 ES ES13817739.9T patent/ES2658974T3/es active Active
- 2013-12-05 CN CN201380066782.2A patent/CN104870435B/zh not_active Expired - Fee Related
- 2013-12-05 EP EP17206218.4A patent/EP3339303B9/en active Active
- 2013-12-05 CU CU2015000062A patent/CU24414B1/es unknown
- 2013-12-05 SG SG11201504076XA patent/SG11201504076XA/en unknown
- 2013-12-05 ES ES17206218T patent/ES2808987T3/es active Active
- 2013-12-05 TR TR2018/02791T patent/TR201802791T4/tr unknown
- 2013-12-05 DK DK17206218.4T patent/DK3339303T3/da active
- 2013-12-05 WO PCT/IB2013/060682 patent/WO2014097041A1/en not_active Ceased
- 2013-12-05 MA MA38175A patent/MA38175B1/fr unknown
- 2013-12-05 MX MX2015008058A patent/MX2015008058A/es active IP Right Grant
- 2013-12-05 HU HUE13817739A patent/HUE038238T2/hu unknown
- 2013-12-05 MD MDA20150052A patent/MD4664C9/ro not_active IP Right Cessation
- 2013-12-05 AU AU2013365908A patent/AU2013365908C1/en not_active Ceased
- 2013-12-05 PE PE2015001044A patent/PE20151090A1/es active IP Right Grant
- 2013-12-05 CA CA2893339A patent/CA2893339C/en active Active
- 2013-12-05 HU HUE17206218A patent/HUE050009T2/hu unknown
- 2013-12-05 EP EP13817739.9A patent/EP2935238B1/en active Active
- 2013-12-05 MY MYPI2015701733A patent/MY176307A/en unknown
- 2013-12-05 PT PT138177399T patent/PT2935238T/pt unknown
- 2013-12-05 SI SI201331756T patent/SI3339303T1/sl unknown
- 2013-12-05 LT LTEP13817739.9T patent/LT2935238T/lt unknown
- 2013-12-05 CR CR20200273A patent/CR20200273A/es unknown
- 2013-12-18 TW TW102146910A patent/TWI546293B/zh not_active IP Right Cessation
- 2013-12-18 US US14/132,567 patent/US9040515B2/en active Active
- 2013-12-19 AR ARP130104902A patent/AR094174A1/es not_active Application Discontinuation
- 2013-12-20 UY UY0001035225A patent/UY35225A/es not_active Application Discontinuation
- 2013-12-20 UY UY0001038712A patent/UY38712A/es not_active Application Discontinuation
-
2014
- 2014-02-28 NO NO14709442A patent/NO2961649T3/no unknown
-
2015
- 2015-03-09 US US14/642,274 patent/US20150175572A1/en not_active Abandoned
- 2015-05-26 CR CR20150279A patent/CR20150279A/es unknown
- 2015-06-16 PH PH12015501367A patent/PH12015501367B1/en unknown
- 2015-06-18 TN TNP2015000281A patent/TN2015000281A1/fr unknown
- 2015-06-18 CL CL2015001733A patent/CL2015001733A1/es unknown
- 2015-06-18 IL IL239520A patent/IL239520B/en active IP Right Grant
- 2015-06-19 MX MX2020002924A patent/MX2020002924A/es unknown
- 2015-06-19 DO DO2015000157A patent/DOP2015000157A/es unknown
- 2015-06-19 GT GT201500190A patent/GT201500190A/es unknown
- 2015-06-19 ZA ZA2015/04437A patent/ZA201504437B/en unknown
- 2015-07-21 EC ECIEPI201531579A patent/ECSP15031579A/es unknown
-
2017
- 2017-05-03 US US15/585,880 patent/US10246433B2/en active Active
-
2018
- 2018-02-05 CY CY20181100137T patent/CY1119883T1/el unknown
- 2018-09-05 ME MEP-2018-8A patent/ME02980B/me unknown
-
2020
- 2020-07-30 HR HRP20201194TT patent/HRP20201194T2/hr unknown
- 2020-08-11 CY CY20201100746T patent/CY1123237T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000281A1 (fr) | Lactames condenses aryliques et heteroaryliques | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| TW201613864A (en) | Novel compounds | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| PH12015500399A1 (en) | Azaindolines | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |